Year-end Sale % OFF 
Abstract
IgE is a key factor in allergic disease, driving manifold elements of the inflammatory cascade. Omalizumab, an anti-IgE monoclonal antibody, has demonstrated efficacy in nasal polyposis (NP) among patients with asthma in a prior smaller study. Efficacy and safety of omalizumab in NP was assessed in two phase III trials (POLYP1 [NCT03280550] and POLYP2 [NCT03280537]).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
